vs
Side-by-side financial comparison of GILAT SATELLITE NETWORKS LTD (GILT) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $152.7M, roughly 1.0× GILAT SATELLITE NETWORKS LTD). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 4.1%, a 67.1% gap on every dollar of revenue.
Gilat Satellite Networks Ltd. is an Israeli public company. It provides satellite-based broadband communications technology, its main expertise being the development, manufacture, and marketing of ground-based satellite systems for global communication via satellites.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
GILT vs STOK — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $152.7M | $158.6M |
| Net Profit | $6.3M | $112.9M |
| Gross Margin | 35.8% | — |
| Operating Margin | 5.4% | 70.2% |
| Net Margin | 4.1% | 71.2% |
| Revenue YoY | — | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $57016808.00 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $152.7M | — | ||
| Q1 25 | — | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q2 24 | $126.6M | — | ||
| Q2 23 | $106.9M | $-2.5M | ||
| Q2 22 | $98.2M | — |
| Q2 25 | $6.3M | — | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 24 | $9.9M | — | ||
| Q2 23 | $-2.0M | $-30.7M | ||
| Q2 22 | $-5.2M | — |
| Q2 25 | 35.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | 39.7% | — | ||
| Q2 23 | 33.8% | — | ||
| Q2 22 | 29.6% | — |
| Q2 25 | 5.4% | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q2 24 | 9.8% | — | ||
| Q2 23 | 0.4% | 1340.7% | ||
| Q2 22 | -4.0% | — |
| Q2 25 | 4.1% | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q2 24 | 7.8% | — | ||
| Q2 23 | -1.9% | 1235.6% | ||
| Q2 22 | -5.3% | — |
| Q2 25 | $57016808.00 | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q2 24 | $56622204.00 | — | ||
| Q2 23 | — | $-0.69 | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.9M | $274.8M |
| Total DebtLower is stronger | $56.5M | — |
| Stockholders' EquityBook value | $315.8M | $350.1M |
| Total Assets | $575.9M | $406.9M |
| Debt / EquityLower = less leverage | 0.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $64.9M | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q2 24 | $93.7M | — | ||
| Q2 23 | $87.4M | $192.1M | ||
| Q2 22 | $70.1M | — |
| Q2 25 | $56.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $2.0M | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | $315.8M | — | ||
| Q1 25 | — | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q2 24 | $282.8M | — | ||
| Q2 23 | $255.0M | $190.2M | ||
| Q2 22 | $245.7M | — |
| Q2 25 | $575.9M | — | ||
| Q1 25 | — | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q2 24 | $416.9M | — | ||
| Q2 23 | $371.6M | $256.9M | ||
| Q2 22 | $376.0M | — |
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | 0.01× | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | — | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 24 | $8.2M | — | ||
| Q2 23 | — | $-21.8M | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 24 | $1.7M | — | ||
| Q2 23 | — | $-22.6M | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q2 24 | 1.3% | — | ||
| Q2 23 | — | 912.5% | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q2 24 | 5.2% | — | ||
| Q2 23 | — | -33.8% | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q2 24 | 0.83× | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
